Bruker
BRKRNASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $62.24 Prior regular-session close from the quote source.
- $61.96–$64.28 Regular-session low and high so far today.
- 2.5M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Feb 11 projected Projected for 2027-02-11 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $32.37–$68.98 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own BRKR if the company arrests a recent collapse in operating profitability and restores free-cash-flow generation.
BRKR price history
Loading recent earnings…
Investment thesis
What must happen next
Bruker’s installed base and recurring service/consumables will continue to generate positive operating cash flow that cushions instrument sale cyclicality and supports valuation.HoldingMateriality: High
Net cash provided by operating activities remained positive at $134,100,000 in FY2025. If recurring service economics hold, Bruker can sustain cash generation through product cycles and validate a premium multiple; if not, revenue becomes far more cyclical and the valuation depends on unrealistic instrument sales growth.
Watch: Large-scale loss of service contracts or substitution by lower-cost competitors (Thermo Fisher, Agilent, Waters or lower-cost vendors) that reduces recurring revenue and service attach.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Net cash provided by operating activities remained positive at $134,100,000 in FY2025.
Open source ↗Gross-margin erosion (product mix, pricing or cost pressure) is the proximate driver of lower profitability and, unless reversed by price increases or a shift to higher-value instruments, will permanently compress operating margins.StrengtheningMateriality: High
Gross profit fell from $1,649,500,000 in FY2024 to $1,577,700,000 in FY2025 despite slightly higher revenue, indicating margin pressure. Sustained lower gross margins translate directly into lower operating income and free cash flow; restoring gross margin is necessary for sustainable profit recovery.
Watch: Successful launch or adoption of new high-margin instrumentation that shifts mix back toward premium products.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Gross profit fell from $1,649,500,000 in FY2024 to $1,577,700,000 in FY2025 despite slightly higher revenue, indicating margin pressure.
Open source ↗The steep fall in operating income is driven largely by identifiable non-recurring items, integration/amortization from acquisitions, or restructuring; if true the core business can recover operating profitability when those items abate.HoldingMateriality: Medium
Operating income dropped from $436,900,000 in FY2023 to $253,100,000 in FY2024 and $68,200,000 in FY2025, showing a sharp deterioration that could include discrete items. If the decline is one-time/transactional, margins can revert and validate the business; if it reflects ongoing structural weakness, operating income will remain low and the multiple is unjustified.
Watch: Ongoing structural SG&A increases or permanently lower instrument ASPs (driven by competition) rather than one-time charges.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating income dropped from $436,900,000 in FY2023 to $253,100,000 in FY2024 and $68,200,000 in FY2025, showing a sharp deterioration that.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Bruker’s installed base and recurring service/consumables will continue to generate positive operating cash flow that cushions instrument sale cyclicality and supports valuation. If recurring service economics hold, Bruker can sustain cash generation through product cycles and validate a premium multiple; if not, revenue becomes far more cyclical and the valuation depends on unrealistic instrument sales growth.
Gross-margin erosion (product mix, pricing or cost pressure) is the proximate driver of lower profitability and, unless reversed by price increases or a shift to higher-value instruments, will permanently compress operating margins. Sustained lower gross margins translate directly into lower operating income and free cash flow; restoring gross margin is necessary for sustainable profit recovery.
The steep fall in operating income is driven largely by identifiable non-recurring items, integration/amortization from acquisitions, or restructuring; if true the core business can recover operating profitability when those items abate. If the decline is one-time/transactional, margins can revert and validate the business; if it reflects ongoing structural weakness, operating income will remain low and the multiple is unjustified.
All standing thesis claims
Original report summary
the company arrests a recent collapse in operating profitability and restores free-cash-flow generation.
Bull case and bear case
Bull case and bear case for Bruker
Where the evidence on Bruker stands: Holding on the latest evidence (Nov 12, 2026). Of its 3 thesis points, 1 strengthening and 2 holding.
Bull case: what the evidence supports
Bruker’s installed base and recurring service/consumables will continue to generate positive operating cash flow that cushions instrument sale cyclicality and supports valuation.
Gross-margin erosion (product mix, pricing or cost pressure) is the proximate driver of lower profitability and, unless reversed by price increases or a shift to higher-value instruments, will permanently compress operating margins.
The steep fall in operating income is driven largely by identifiable non-recurring items, integration/amortization from acquisitions, or restructuring; if true the core business can recover operating profitability when those items abate.
Bear case: what would count against it
Large-scale loss of service contracts or substitution by lower-cost competitors (Thermo Fisher, Agilent, Waters or lower-cost vendors) that reduces recurring revenue and service attach.
Successful launch or adoption of new high-margin instrumentation that shifts mix back toward premium products.
Ongoing structural SG&A increases or permanently lower instrument ASPs (driven by competition) rather than one-time charges.
Thesis-Break Engine
What has broken in Bruker’s thesis
Each break OptimistFi flagged on Bruker, dated — with what has historically followed the same kind of break across the market, not a forecast for Bruker.
- Operating-margin compression
Across all companies, this kind of break has happened 10,660 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 36% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Bruker’s latest quarterly report, ahead of the annual figure it is written on.
- Operating-margin compression, trailing 12 months
Across all companies, this kind of early warning has happened 2,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 36% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedOther material event.
Bruker filed an SEC 8-K on 2026-11-05: Other material event. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Bruker filed an SEC 8-K on 2026-11-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedOther material event.
Bruker filed an SEC 8-K on 2026-10-29: Other material event. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large-scale loss of service contracts or substitution by lower-cost competitors (Thermo Fisher, Agilent, Waters or lower-cost vendors) that reduces recurring revenue and service attach.
- Successful launch or adoption of new high-margin instrumentation that shifts mix back toward premium products.
- Ongoing structural SG&A increases or permanently lower instrument ASPs (driven by competition) rather than one-time charges.
BRKR news
Loading headlines…
Financial statements
BRKR income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
BRKR: quick answers
- When does Bruker (BRKR) report earnings next?
- Bruker's next results are projected for February 11, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 4, 2026. Earnings calendar
- What is BRKR's short interest?
- As of October 30, 2026, 11.3M BRKR shares were sold short, 7.37% of its shares outstanding, down 11.2% from the count before. At the stock's average daily volume that is 5.4 days to cover. FINRA publishes the count twice a month. BRKR short interest history
- Have members of Congress traded BRKR?
- 7 trades in BRKR have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed BRKR trade
- Which well-known investors own BRKR?
- 3 of the 37 well-known funds tracked here reported BRKR shares in their latest 13F filings. By share of the fund's portfolio: Glenview Capital Management, 0.3%; Viking Global Investors (Andreas Halvorsen), 0.1%; Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios
BRKR in well-known investors’ portfolios
3 of 37 funds reported BRKR shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Glenview Capital Management | 0.28% | $15.2M | New | Q2 2026 |
| Andreas HalvorsenViking Global Investors | 0.15% | $53.8M | New | Q2 2026 |
| Ray DalioBridgewater Associates | 0.01% | $2.5M | New | Q2 2026 |